Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a daily probiotic help adults with autism reach personal goals?

NCT ID NCT07064538

Symptom relief Sponsor: Mackay Memorial Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a probiotic supplement called Neuralli® MP can help adults aged 18 to 50 who have autistic traits. Participants take two capsules daily and set their own personal goals to track progress. The trial is small and open-label, meaning everyone knows they are getting the supplement, so results will be preliminary.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Neuralli® MP (probiotic supplement containing 60 billion CFU per day)
What this could lead to
If it works, this could point toward a simple dietary supplement that helps adults with autistic traits achieve personal goals and improve daily functioning.
What could go wrong
This is a very small, open-label trial with only 15 participants and no placebo group, so results may be due to expectation effects. The supplement is not a cure and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 15 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants aged between 18 and 50 who exhibit autistic traits * Those who have the willingness and ability to work but have not yet been able to enter a sheltered workshop at the Kanner Foundation * The subjects, primary caregivers and institution staff are willing to participate in the study, and the primary caregivers and institution staff are willing to fill out the questionnaire and accept the interview Exclusion Criteria: * Those who have taken antibiotics or probiotic products in powder, capsule or tablet form within the past month are excluded. * Participants currently receiving antibiotic treatment are also excluded. * Individuals with a known allergy to dairy products. * Individuals with immunodeficiency or compromised immune function. * Individuals diagnosed with small intestinal bacterial overgrowth (SIBO) * Ineligibility determined by PI, e.g. the individual starts any new medication or therapy, especially related to their autism, during this time.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial septal defect autism autism spectrum disorder pervasive developmental disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASD Autism Autistic disorders spectrum

Contacts and locations

Locations

  • Mackay Memorial Hospital

    Taipei, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.